AutoIVF, a fertility technology company dedicated to advancing access to assisted reproductive care, has announced the receipt of a Phase IIB Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH). The grant is supported by the Eunice Kennedy Shriver National Institute of Child Health & Human Development under Award Number R44HD105529.
This NIH funding will facilitate the commercialization of AutoIVF’s flagship platform, OvaReady—an automated desktop system designed to optimize egg identification and preparation for in vitro fertilization (IVF). The platform aims to enable decentralized egg retrieval, thereby broadening access to fertility care beyond conventional IVF laboratory environments. The device remains under development and is not yet available for purchase in the United States.
Under the leadership of CEO Ravi Kapur, Ph.D., FAIMBE, AutoIVF’s team collectively possesses over 200 years of expertise in IVF, microfluidics, and reproductive health. The company remains committed to enhancing global accessibility to fertility care.
KEY QUOTES:
“The NIH’s sustained support over the past five years—from early feasibility to commercialization—reinforces the scientific merit and clinical potential of our approach. We’re proud to be driving innovations intended to improve care for patients undergoing infertility treatment or fertility preservation.”
Emre Ozkumur, Ph.D., Vice President of R&D at AutoIVF
“Being selected through the NIH’s highly competitive review process shows the real potential the technology has to improve outcomes for patients, doctors, and the broader fertility field. With decades of experience as IVF physicians, we see OvaReady as a game changer – making it easier and more efficient to identify and prepare eggs for IVF and fertility preservation.”
Co-founders Drs. Thomas Toth, Michael Alper, and Alan Penzias
